Reva is expanding commercial access to the Fantom bioresorbable scaffold with a new distribution partnership in Italy. The company will work with Bio Vascular on commercial activities nationwide. Following this agreement, the first commercial implant procedure in Italy was conducted by Bernardo Cortese (Clinica San Carlo – Casa di Cura Polispecialistica, Paderno Dugnano, Italy).
The partnership with Bio Vascular expands REVA’s commercial activities to Italy and builds on sales efforts already underway in Germany, Switzerland, Austria and Turkey. Under the terms of the partnership, Bio Vascular will be Reva’s distribution partner for the Fantom and Fantom Encore bioresorbable scaffolds in Italy. Bio Vascular will be responsible for all sales, marketing, customer training, and support. Commercial sales are expected to ramp-up in the fourth quarter of 2018, following successful completion of Reva’s training programme by Bio Vascular personnel.
Cortese says: “In Italy, we stay on the leading edge of technology to offer the best possible care to our patients. During the implant procedure, I was able to see the technical advantages of Fantom over first-generation bioresorbable scaffolds such as x-ray visibility and ease-of-use. Second-generation, thin strut bioresorbable scaffolds like Fantom have the potential to improve outcomes, and we are excited to have this treatment option available for Italian patients.”
Reggie Groves, Reva’s CEO, comments: “With this partnership we are delivering on our ongoing commitment to expand geographic access to Fantom. Bio Vascular offers country-wide distribution coverage in Italy. The company’s proven track record with interventional cardiology devices, demonstrated relationships with physicians and commitment to patient care make it an ideal partner for us.”
